Paratek Pharmaceuticals — Transcept Pharmaceuticals — Investor Presentation (September 2013)
27 slides from Paratek Pharmaceuticals's investor presentation, Sep 25, 2013
Slide 1: Specialty pharmaceutical company focused on neuroscience
September 2013 A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience NASDAQ:TSPT
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future re
Slide 3: Neuroscience focused specialty pharmaceutical company
Transcept Pharmaceuticals: Neuroscience focused specialty pharmaceutical company 3 First and only product approved for middle of the night insomnia US primary care marketing agreement: Purdue Pharma INTERMEZZO® for MOTN insomnia ~$78MM in cash as of 6/30/13; no debt Strong balance sheet Succ
Slide 4: Proprietary nasal powder drug delivery technology
Proprietary nasal powder drug delivery technology
Slide 5: Nasal drug delivery: significant market opportunity
Nasal drug delivery Significant market opportunity U.S. nasal Rx drug delivery market estimated > $3B in 2013 Nasal cavity: potentially efficient drug delivery path – Nasal mucosa is permeable and leads to a significant vascular capillary bed – Safety advantages vs. e.g., pulmonary delivery Ho
Slide 6: Shin Nippon Biomedical Laboratories: Optimizing nasal drug delivery
Shin Nippon Biomedical Laboratories: Optimizing nasal drug delivery Major Contract Research Organization with over 2,000 employees across the United States, Asia and Europe Established 1957 Provides comprehensive range of non-clinical and clinical development services to biopharmaceutical comp
Slide 7: SNBL nasal powder drug delivery system
SNBL nasal powder drug delivery system: Proprietary muco-adhesive carrier + novel delivery device 7 SNBL carrier technology – Dry powder formulation – Effective muco-adhesive carrier – Consists of generally recognized as safe “GRAS” components – Excellent safety profile demonstrated – Portfolio of
Slide 8: SNBL nasal powder: superior bioavailability in primates
SNBL nasal powder drug delivery system: superior bioavailability to traditional nasal sprays in primates 8 Zolmitriptan in primates (Migraine) Calcitonin in primates (Osteoporosis) 0 200 400 600 800 1000 1200 0 120 240 360 480 P las m a c o n c e n tra ti o n (n g /m L ) Zomig® Nasal Spray (5mg/anim
Slide 9: Human studies confirm primate PK results
0 1 2 3 4 5 6 7 8 9 0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 Zo lmi tri p ta n Co n ce n tr at io n ( n g /m L) Time (h) TRZ 0.75 mg TRZ 1.5 mg TRZ 3.0 mg Zomig NS 5 mg 9 SNBL nasal powder delivery system: Human studies confirm primate PK results SNBL zolmitriptan powder 0.75 mg SNBL nasa
Slide 10: TO-2070: rapid and sustained relief of acute migraine
TO-2070: designed for rapid and sustained relief of acute migraine
Slide 11: Migraine: large market with significant unmet needs
Migraine: large market with significant unmet needs 11 US and Western Europe 1-year prevalence:11% overall1 – According to a WHO survey, a day with severe migraine is as disabling as a day with quadriplegia2 In US each year: ~30MM cases; $2.6B Rx product sales3 ~80% of migraine Rx patients wou
Slide 12: DHE: a trusted treatment for migraine
DHE: a trusted treatment for migraine Need for improved delivery systems 12 DHE has long been recognized as an effective treatment for migraine – Approved for use in the United States since 1946 – Frequently used by migraine specialists in triptan failures Poor oral bioavailability – Generally a
Slide 13: TO-2070: a better way to deliver DHE for migraine
TO-2070: a better way to deliver DHE for migraine Rapidly absorbed – Bioavailability expected to be comparable to IM and pulmonary (LevadexTM) – Superior to conventional nasal sprays Sustained efficacy – DHE is associated with lower recurrence rates versus triptans1 – Sustained high bioavailabil
Slide 14: TO-2070 rapid and consistent absorption in primates
0.01 0.1 1 10 100 0 1 2 3 4 5 6 7 8 P la sm a c on ce nt ra tion (n g/ m L) Time (hrs) IV (0.1 mg) TO-2070 (0.1mg) TO-2070 shows rapid and consistent absorption in primates (n=6) (Median Tmax = 17.5 minutes) 14
Slide 15: TO-2070 vs Migranal liquid nasal spray in primates
0 1 2 3 4 5 6 0 1 2 3 4 P la s m a c o n c e n tr a tion +/- S E (n g /m L ) Time (hrs) TO-2070 (0.5mg) Migranal (0.5mg) TO-2070 vs Migranal® liquid nasal spray in primates: Earlier Cmax with twice the drug exposure in first 30 minutes 15 Ratio 2:1 0-30 minute AUC data 0-4 hour plasma profile primat
Slide 16: TO-2070 vs DHE intramuscular injection in primates
0.1 1 10 0 1 2 3 Pla sm a c on ce nt ra tion (n g/ m L) Time (hrs) IM (0.1mg) TO-2070 (0.5mg) TO-2070 vs DHE intramuscular injection (IM) in primates: Comparable PK profiles 0 to 3 hours 16 TO-2070 (primate data, n=6) TO-2070
Slide 17: Allergan's Levadex (under FDA review)
Allergan’s Levadex (under FDA review) Developed by MAP Pharmaceuticals; acquired by Allergan for ~$1.0 B (2013) Pulmonary inhalation DHE product Approval expected mid-2014 Anticipated pricing >$75 - 100 per dose Allergan and analysts forecast $500MM in peak US sales 17 Potential drawbacks
Slide 18: TO-2070 initial development program
TO-2070 initial development program License agreement signed September, 2013 IND target date: 1H 2014 Human PK data expected: 2H 2014 NDA strategy to be finalized following FDA meeting Potential for 505(b)(2) regulatory pathway based on well- characterized nature of DHE 18
Slide 19: Initial Key Opinion Leader feedback on DHE nasal powder
Initial Key Opinion Leader (KOL) feedback regarding DHE nasal powder for acute migraine
Slide 20: Summary of Key Opinion Leader feedback
Summary of Key Opinion Leader (KOL) feedback Migraine KOLs believe that DHE is an excellent treatment for many migraine patients, but better dosage forms are needed Experts believe that the SNBL intranasal delivery technology applied to DHE offers promise for improving the management of acute mi
Slide 21: INTERMEZZO
INTERMEZZO® Transcept
Slide 22: Intermezzo: first and only sleep aid approved for middle-of-the-night dosing
Intermezzo: the first and only prescription sleep aid approved for middle-of-the-night dosing 22
Slide 23: Intermezzo: approved for middle-of-the-night dosing
Intermezzo: the first and only sleep aid approved for middle-of-the night dosing Novel and patent-protected zolpidem formulation – Sublingual tablet – Bicarbonate-carbonate buffers Approved dose – 1.75 mg in women & patients > 65 years – 3.5 mg in men < 65 years Rapidly absorbed in both men an
Slide 24: Intermezzo: challenges & opportunities
Intermezzo: challenges & opportunities Despite Purdue’s promotional effort and investment, INTERMEZZO has yet to achieve sales expectations / potential – For highest prescribers of hypnotics, insomnia is usually not the primary reason that patient is being seen by the physician – Low physician awa
Slide 25: Financial position June 30, 2013
Financial position June 30, 2013 Cash, equivalents & investments: ~$78MM Shares outstanding 19 M Options / warrants / other: 4 M Total: 23 M Employees (FTEs): 12.5 25
Slide 26: Neuroscience focused specialty pharmaceutical company
Transcept Pharmaceuticals: Neuroscience focused specialty pharmaceutical company 26 First and only product approved for middle of the night insomnia Marketed in US under partnership with Purdue Pharma INTERMEZZO® for MOTN insomnia ~$78MM in cash as of 6/30/13; no debt Strong balance sheet Su
Slide 27: Specialty pharmaceutical company focused on neuroscience
A specialty pharmaceutical company focused on the development and commercialization of proprietary products to address important therapeutic needs in the field of neuroscience NASDAQ:TSPT September 2013
Transcept Pharmaceuticals — Investor Presentation (September 2013) on 6ix